A randomized, double-blind, placebo-controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder.

ABSTRACT:

Background

In a previous study, ondansetron, a serotonin 5-HT₃ receptor antagonist, reduced drinking intensity (drinks/drinking day [DPDD]) among European-ancestry (EA) participants with moderate-to-severe alcohol use disorder (AUD) and variants in genes encoding the serotonin transporter (SLC6A4) and 5-HT_3A (HTR3A), and 5-HT_3B (HTR3B) receptors. We tested whether (1) ondansetron reduces DPDD among individuals of either European or African ancestry (AA), and (2) that reductions in DPDD are greatest among ondansetron-treated individuals with population-specific combinations of genotypes at SLC6A4, HTR3A, and HTR3B.

Methods

In this 16-week, double-blind, placebo-controlled, parallel-group clinical trial, adults with AUD were randomized to recei

SUBMITTER: Seneviratne C 

PROVIDER: S-EPMC9901168 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature